UroGen Pharma Ltd.
URGN
$19.69
-$0.095-0.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.91% | -16.88% | -58.46% | 29.13% | -3.46% |
| Total Depreciation and Amortization | 19.92% | 62.42% | 15.04% | 1.14% | -25.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.87% | -60.65% | 50.89% | -19.47% | 67.26% |
| Change in Net Operating Assets | 416.34% | -111.90% | 261.85% | -447.43% | 173.38% |
| Cash from Operations | 5.23% | -208.57% | 50.77% | -16.49% | 25.17% |
| Capital Expenditure | -220.45% | 61.74% | -19.79% | -14.29% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 210.14% | -142.67% | 156.95% | -982.75% | -10.62% |
| Cash from Investing | 209.41% | -142.83% | 156.79% | -989.73% | -11.24% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 761.76% | -52.11% | -99.53% | -81.48% | 49.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Financing | 770.59% | -52.11% | -99.82% | -60.51% | 83.48% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.63% | -244.36% | 149.65% | -207.09% | 142.96% |